Volume 27, Issue 1 pp. 19-23
ORIGINAL ARTICLE

Effectiveness of SARS-CoV-2 vaccines on hemodialysis patients in Japan: A nationwide cohort study

Kan Kikuchi

Corresponding Author

Kan Kikuchi

Division of Nephrology, Shimoochiai Clinic, Tokyo, Japan

Correspondence

Kan Kikuchi, Division of Nephrology, Shimoochiai Clinic, Tokoyo, Japan.

Email: [email protected]

Search for more papers by this author
Masaomi Nangaku

Masaomi Nangaku

Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan

Search for more papers by this author
Munekazu Ryuzaki

Munekazu Ryuzaki

Department of Nephrology, Tokyo Saiseikai Central Hospital, Tokyo, Japan

Search for more papers by this author
Tomoyuki Yamakawa

Tomoyuki Yamakawa

Kidney Center, Shirasagi Hospital, Tokyo, Japan

Search for more papers by this author
Ota Yoshihiro

Ota Yoshihiro

Nagoya Memorial Hospital, Nagoya, Japan

Search for more papers by this author
Norio Hanafusa

Norio Hanafusa

Department of Blood Purification, Tokyo Women's Medical University, Tokyo, Japan

Search for more papers by this author
Ken Sakai

Ken Sakai

Department of Nephrology, Toho University Faculty of medicine, Tokyo, Japan

Search for more papers by this author
Yoshihiko Kanno

Yoshihiko Kanno

Department of Nephrology, Tokyo Medical University, Tokyo, Japan

Search for more papers by this author
Ryoichi Ando

Ryoichi Ando

Department of Nephrology, Seishokai Memorial Hospital, Tokyo, Japan

Search for more papers by this author
Toshio Shinoda

Toshio Shinoda

Faculty of Medical and Health Sciences, Tsukuba International University, Tsukuba, Japan

Search for more papers by this author
Shu Wakino

Shu Wakino

Department of Nephrology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan

Search for more papers by this author
Hidetomo Nakamoto

Hidetomo Nakamoto

Department of General Internal Medicine, Saitama Medical University, Saitama, Japan

Search for more papers by this author
Yoshiaki Takemoto

Yoshiaki Takemoto

Department of Urology, Graduate School of Medicine Shirasagi Hospital, Osaka City University, Osaka, Japan

Search for more papers by this author
Tadao Akizawa

Tadao Akizawa

Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan

Search for more papers by this author
COVID-19 Task Force Committee of the Japanese Association of Dialysis Physicians, the Japanese Society for Dialysis Therapy, and the Japanese Society of Nephrology

COVID-19 Task Force Committee of the Japanese Association of Dialysis Physicians, the Japanese Society for Dialysis Therapy, and the Japanese Society of Nephrology

Search for more papers by this author
First published: 24 May 2022
Citations: 10

Abstract

Introduction

This study compared the outcomes of dialysis patients who received SARS-CoV-2 vaccine with those who did not use data from the Japanese COVID-19 registry.

Methods

A total of 1260 dialysis patients with confirmed positive SARS-CoV-2 infection was included in this study. Patients were divided into two groups: patients who experienced breakthrough infection and those who were unvaccinated. The need of oxygen supplementation and mortality risks were compared using multivariate logistic regression analysis.

Results

The mortality rate was 24.2% in unvaccinated patients and 8.6% in breakthrough patients. The odds ratio of need of oxygen supplementation in the breakthrough patients relative to unvaccinated patients was 0.197. The hazard ratio of mortality in the breakthrough patients relative to unvaccinated patients was 0.464.

Conclusion

Our prospective observational study showed that SRAS-CoV-2 vaccination in hemodialysis patients is vital for reducing need of oxygen supplementation and mortality risk.

CONFLICT OF INTEREST

The authors have no conflicts of interest directly relevant to the content of this article.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.